Vaccine yielded encouraging long-term survival rates in certain patients with NSCLCApril 04, 2012
"This is a novel immunotherapy that appears to show unusually long survival in some patients," said Lyudmila Bazhenova, M.D., associate clinical professor at the University of California-San Diego Moores Cancer Center in La Jolla, Calif.
These findings represent an updated long-term survival analysis on patients treated with belagenpumatucel-L, a cell-based allogeneic vaccine derived from four lung cancer cell lines. The open-label study included 75 patients with non-small cell lung cancer (NSCLC) - two patients with stage 2 disease, 12 with stage 3A, 15 with stage 3B and 46 with stage 4. The researchers randomly assigned patients to three dose cohorts: 1.25, 2.5 or 5 × 107 cells/injection.
For all patients, median survival was 14.5 months, and the five-year survival rate was 20 percent. The 40 patients with stage 3B/4 cancer enrolled in the second and third dose cohorts had a median survival of 15.9 months and a one-year survival rate of 61 percent, a two-year survival rate of 41 percent and a five-year survival rate of 18 percent.
Patients with stage 3B/4 nonprogressive disease after chemotherapy had a median survival of 44.4 months; five-year survival was 50 percent, which is "unheard of for patients with NSCLC," Bazhenova said.
In contrast, patients who progressed after front-line chemotherapy had a median survival rate of 14.1 months and a 9.1 percent five-year survival rate.
Bazhenova said that although these results are intriguing, they must be confirmed in a phase III clinical trial, which is currently under way in eight countries.
American Association for Cancer Research
Related Non-small Cell Lung Cancer Current Events and Non-small Cell Lung Cancer News Articles
Multimodality treatment for metastatic lung cancer with surgery may improve survival rates
Patients diagnosed with an advanced form of metastatic non-small cell lung cancer (NSCLC) may benefit from surgical resection (removal of all or part of the lung) in combination with chemotherapy and radiation therapy, according to an article in the June 2015 issue of The Annals of Thoracic Surgery.
Stereotactic Ablative Radiotherapy achieves better overall survival than surgery for early lung cancer
Patients with operable stage I non-small cell lung cancer (NSCLC) could achieve better overall survival rates if treated with Stereotactic Ablative Radiotherapy (SABR) rather than the current standard of care -- invasive surgery -- according to research from a phase III randomized international study from The University of Texas MD Anderson Cancer Center.
Experimental immunotherapy shows high response rate in advanced lung cancer
An early phase study testing an anti-PDL1 agent in combination with standard chemotherapy in the treatment of advanced non-small cell lung cancer has provided promising early results, prompting multiple phase III studies in lung cancer.
ASTRO issues guideline on definitive and adjuvant RT for locally advanced non-small cell lung cancer
The American Society for Radiation Oncology (ASTRO) is issuing a new guideline, "Definitive and adjuvant radiotherapy in locally advanced non-small cell lung cancer: An American Society for Radiation Oncology (ASTRO) evidence-based clinical practice guideline."
Multiple types of resistance to new lung cancer drug identified
After identifying three different types of resistance to a promising investigational lung cancer drug in a phase 1 trial, a team of researchers led by Dana-Farber Cancer Institute scientists say new targeted inhibitors and combinations are urgently needed to stay ahead of tumors' constant and varied molecular shape-shifting.
Profiling approach to enable right lung cancer treatment match
Manchester researchers have tested a new way to genetically profile lung cancer samples, potentially allowing doctors to more easily identify the most appropriate treatment for patients.
Pneumonectomy or lobectomy?
For patients in the early stage of non-small cell lung cancer, surgical resection yields optimal outcomes. Prior investigations have shown that different resection procedures have very different outcomes, with pneumonectomy associated with three-fold higher mortality than other resection types.
MD Anderson study points to potential new lung cancer therapy
New findings about regulation of PD-L1, a protein that allows cancer to evade the immune system, has shown therapeutic promise for several cancers, including the most common form of lung cancer.
Driver of non-small cell lung cancer, FGFR1, also in 23 percent of small cell lung cancer
Significant new treatments are available or in clinical trials for non-small cell lung cancer. The same explosion in treatment options is not true for the disease's cousin, small cell lung cancer, the less common and more aggressive form of the disease.
Anti-fungal drug shows promise as potential new cancer treatment
A common anti-fungal treatment has joined the ranks of drugs that may be suitable for use in treating cancer, according to research from the Repurposing Drugs in Oncology (ReDO) project published in ecancermedicalscience.
More Non-small Cell Lung Cancer Current Events and Non-small Cell Lung Cancer News Articles